ClinicalTrials.gg
RecruitingNCT07845071Updated Oct 23, 2026

An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin

A Phase 3 interventional study of Cebranopadol 400 ug in Pain, sponsored by Adneuris Therapeutics, Inc.. Recruiting at 15 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Adneuris Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 23, 2026Site recruiting status changedStudy contact changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,882 studies in Pain with a site in United States — 313 open to participants now, 392 under way, 24 of them phase 3. Pain · United States.

Planned enrollment
602nd of 2,560
160 · median 66
Started
2026
with 112 others
Phase 3
343 of 2,882
17 open now
Primary completion
2027-01
later than 136 of 391 live
Registered
2,870th of 2,882
by date

Among the 2,882 studies in Pain with a site in United States, this one is the 602nd largest by planned enrollment of the 2,560 interventional ones that give a count, is one of 113 that started in 2026, is one of 343 in phase 3, reaches primary completion later than 136 of the 391 other live ones, and was the 2,870th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

313 of the 2,882 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

307 more — sign in →

All 313 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,882 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of cebranopadol in treating acute pain.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 to 75 years of age.
  • Able to provide .
  • Experiencing moderate to severe acute pain related to: 1) An ambulatory surgical procedure expected to cause pain lasting at least 72 hours, or 2) A traumatic or non-traumatic musculoskeletal condition.
  • Have a pain score of at least 4 on a 0 to 10 pain rating scale before starting study treatment.
  • Willing and able to comply with study requirements

Exclusion criteria

Exclusion Criteria:

  • Chronic pain condition that requires ongoing pain medication.
  • Significant medical or psychiatric condition that could affect participation or study results.
  • History of substance use disorder or misuse of alcohol or drugs.
  • Current use of medications that may interfere with the study drug or pain assessments.
  • Known allergy or intolerance to cebranopadol or permitted rescue pain medications.
  • Pregnant or breastfeeding.
  • Participation in another clinical trial or receipt of an drug within the protocol-defined period before study entry.
  • Any condition that, in the investigator's opinion, would make participation unsafe or interfere with study assessments.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Cebranopadol

    Participants receive Cebranopadol 400 µg Starting dose 400 mcg once per day for 14 days or until pain resolves, whichever occurs first.

    Drug: Cebranopadol 400 ug

Interventions

  • Participants receive Cebranopadol 400 mcg once per day for 14 days or until pain resolves, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Sum of pain intensity differences through 48 hours (SPID48)

    Sum of pain intensity differences through 48 hours (SPID48), calculated from NPRS assessments collected following the first administration of cebranopadol.

    Time frame: From 0 through 48 hours

07

Study locations

15 of 15 sites recruiting
  • Adneuris Site 001115
    Phoenix, Arizona 85053, United States
    Recruiting
  • Adneuris Site 001118
    Riverside, California 92504, United States
    Recruiting
  • Adneuris Site 001119
    Longmont, Colorado 80501, United States
    Recruiting
  • Adneuris Site 001122
    Savannah, Georgia 31406, United States
    Recruiting
  • Adneuris Site 001123
    O'Fallon, Illinois 62269, United States
    Recruiting
  • Adneuris Site 001125
    Annapolis, Maryland 21401, United States
    Recruiting
  • Adneuris Site 001120
    Oradell, New Jersey 07649, United States
    Recruiting
  • Adneuris Site 001124
    Tulsa, Oklahoma 74137, United States
    Recruiting
  • Adneuris Site 001110
    Bellaire, Texas 77401, United States
    Recruiting
  • Adneuris Site 001117
    Forney, Texas 75126, United States
    Recruiting
  • Adneuris Site 001104
    McAllen, Texas 78501, United States
    Recruiting
  • Adneuris Site 001116
    Plano, Texas 75093, United States
    Recruiting
  • Adneuris Site 001111
    San Antonio, Texas 78240, United States
    Recruiting
  • Adneuris Site 001121
    San Antonio, Texas 78240, United States
    Recruiting
  • Adneuris Site 001101
    Salt Lake City, Utah 84107, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Only IPD used in the results publication

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jan 2027, 4 months after the start.

Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's planned 4 months is below that.

Counting every sponsor, half of 215 studies reached it within 18 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 28, 2026
StartActual
Sep 22, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Feb 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
14 sites changed recruiting status (14 now recruiting)
Show 14 sites
  • Adneuris Site 001115 · Phoenix, United StatesNot yet recruiting→Recruiting
  • Adneuris Site 001118 · Riverside, United StatesNot yet recruiting→Recruiting
  • Adneuris Site 001119 · Longmont, United StatesNot yet recruiting→Recruiting
  • Adneuris Site 001125 · Annapolis, United StatesNot yet recruiting→Recruiting
  • Adneuris Site 001120 · Oradell, United StatesNot yet recruiting→Recruiting
  • Adneuris Site 001124 · Tulsa, United StatesNot yet recruiting→Recruiting
  • Adneuris Site 001117 · Forney, United StatesNot yet recruiting→Recruiting
  • Adneuris Site 001122 · Savannah, United StatesNot yet recruiting→Recruiting
  • Adneuris Site 001110 · Bellaire, United StatesNot yet recruiting→Recruiting
  • Adneuris Site 001111 · San Antonio, United StatesNot yet recruiting→Recruiting
  • Adneuris Site 001121 · San Antonio, United StatesNot yet recruiting→Recruiting
  • Adneuris Site 001101 · Salt Lake City, United StatesNot yet recruiting→Recruiting
  • Adneuris Site 001123 · O'Fallon, United StatesNot yet recruiting→Recruiting
  • Adneuris Site 001116 · Plano, United StatesNot yet recruiting→Recruiting
across 3 updates, Sep 30, 2026 – Oct 23, 2026
Contact
Study contact's phone or email changed: T•••@trispharma.com→c•••@trispharma.com; T•••@trispharma.com→c•••@trispharma.com. See the current contact
Oct 13, 2026
Registered
First appeared on the registry
Sep 28, 2026
Show all 4 updates
  1. Oct 23, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Adneuris Site 001123 · O'Fallon, United StatesNot yet recruiting→Recruiting
    • Adneuris Site 001116 · Plano, United StatesNot yet recruiting→Recruiting
  2. Oct 13, 2026
    5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • Adneuris Site 001122 · Savannah, United StatesNot yet recruiting→Recruiting
    • Adneuris Site 001110 · Bellaire, United StatesNot yet recruiting→Recruiting
    • Adneuris Site 001111 · San Antonio, United StatesNot yet recruiting→Recruiting
    • Adneuris Site 001121 · San Antonio, United StatesNot yet recruiting→Recruiting
    • Adneuris Site 001101 · Salt Lake City, United StatesNot yet recruiting→Recruiting
    Contact Study contact's phone or email changed: T•••@trispharma.com→c•••@trispharma.com; T•••@trispharma.com→c•••@trispharma.com. See the current contact
    + 1 other change: verification date
  3. Sep 30, 2026
    7 sites changed recruiting status (7 now recruiting)
    Show 7 sites
    • Adneuris Site 001115 · Phoenix, United StatesNot yet recruiting→Recruiting
    • Adneuris Site 001118 · Riverside, United StatesNot yet recruiting→Recruiting
    • Adneuris Site 001119 · Longmont, United StatesNot yet recruiting→Recruiting
    • Adneuris Site 001125 · Annapolis, United StatesNot yet recruiting→Recruiting
    • Adneuris Site 001120 · Oradell, United StatesNot yet recruiting→Recruiting
    • Adneuris Site 001124 · Tulsa, United StatesNot yet recruiting→Recruiting
    • Adneuris Site 001117 · Forney, United StatesNot yet recruiting→Recruiting
    + 1 other change: date precision
  4. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07845071
Lead sponsor
Adneuris Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Sep 22, 2026
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Study Director, Adneuris Therapeutics
Contact
clinicaltrials@trispharma.com
732-940-2800
Emilio Quetglas, MD
Contact
clinicaltrials@trispharma.com
732-940-2800

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cebranopadol

Start the discussion